Product Information
MICROGESTIN 21 1.5-30 TAB is a generic product labeled by Mayne Pharma, priced at $0.4097 per EA under NDC 51862087201. Its NADAC has been published 194 times since Oct 20, 2021.
FDA first approved this application on Mar 20, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Mayne PharmaNDC
51862087201
Classification
Generic
Dosage Form
KIT
Effective Date
6/18/2025
Approval Type
Generic (ANDA)
FDA Application
ANDA202996FDA Approved
3/20/2014
TE Code
AB
On Market Since
10/11/2020
Price Statistics
The NADAC for MICROGESTIN 21 1.5-30 TAB has been published 194 times since Oct 20, 2021, and over the history we have for it it has declined 20.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4097 per EA |
|---|---|
| All-time high | $0.6344 (Jan 12, 2022) |
| All-time low | $0.3066 (Jul 17, 2024) |
| Median price | $0.5094 |
| Average price | $0.4830 |
| Largest weekly change | +67.3% (Aug 21, 2024) |
| Weeks tracked | 194 |
| Tracking since | Oct 20, 2021 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-18.0%
5Y
N/A
All
-20.2%
Last surveyed Jul 2, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 58% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mayne Pharma manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone Acetate/Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MICROGESTIN 21 1.5-30 TAB?
The current National Average Drug Acquisition Cost (NADAC) for MICROGESTIN 21 1.5-30 TAB, manufactured by Mayne Pharma, is $0.4097 per EA (NDC 51862087201), effective Jul 2, 2025.
How has the price of MICROGESTIN 21 1.5-30 TAB changed over time?
Over the history we have for it, the NADAC for MICROGESTIN 21 1.5-30 TAB has declined 20.2%. It has been tracked across 194 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for MICROGESTIN 21 1.5-30 TAB?
Since Oct 20, 2021, the NADAC for MICROGESTIN 21 1.5-30 TAB has ranged from a low of $0.3066 (Jul 17, 2024) to a high of $0.6344 (Jan 12, 2022), with a median of $0.5094 per EA.
Are there cheaper alternatives to MICROGESTIN 21 1.5-30 TAB?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MICROGESTIN 21 1-20 TABLET, is $0.1703 per EA — about 58% below MICROGESTIN 21 1.5-30 TAB.
Who manufactures MICROGESTIN 21 1.5-30 TAB?
MICROGESTIN 21 1.5-30 TAB (NDC 51862087201) is labeled by Mayne Pharma, and CMS classifies it as a generic product.